Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare and digital health company focused on portable, semiconductor-based ultrasound technology and ultrasound software solutions. The Butterfly Network news feed on Stock Titan highlights company announcements that relate to its handheld ultrasound devices, Ultrasound-on-Chip™ semiconductor platform, enterprise software and AI initiatives.
Investors and healthcare professionals following BFLY news will see updates on financial results and guidance, such as quarterly earnings releases and preliminary revenue expectations furnished through press releases and 8-K filings. These items often include commentary on revenue growth, cash usage, chip development milestones and the progress of enterprise offerings like Compass™ and Compass AI™.
News coverage also features product and platform developments, including launches of new software capabilities such as Compass AI, announcements about AI-enabled clinical tools like Auto B-line Counter or a Gestational Age AI tool, and information about developer-focused initiatives like Butterfly Garden™ and the planned Beam Steering API. These stories provide insight into how Butterfly is expanding its imaging platform and exposing core capabilities to partners and developers.
Another recurring theme in Butterfly Network news is global health and clinical impact. Press releases describe programs in Sub-Saharan Africa involving handheld probes, training and AI tools for obstetric ultrasound, as well as clinical publications that examine how Butterfly’s devices and software can affect workflows, costs and provider economics in hospital systems.
In addition, the BFLY news stream includes capital markets and corporate updates, such as participation in healthcare investor conferences, executive appointments and SEC-reported events like the NYSE’s decision to delist Butterfly’s public warrants while leaving the common stock listing under BFLY unchanged. For readers tracking Butterfly Network, this page offers a consolidated view of operational, financial, technological and regulatory developments as they are publicly disclosed.
Butterfly Network, Inc. (NYSE: BFLY) reported a 14% revenue growth in the first quarter of 2024, exceeding expectations. The company achieved record revenue of $17.7 million, reduced net loss by 35%, and net cash used in operations by 52%. They successfully launched the Butterfly iQ3™ and ScanLab™ training app, received EU MDR certification, and announced plans to expand into the European market. Butterfly Network's recent operational highlights include FDA clearance for the Butterfly iQ3™, EU MDR certification for the Butterfly iQ+, and the launch of ScanLab™. The company's gross profit was $10.3 million, with a gross margin of 58.2%. Operating expenses decreased by 25% to $32.9 million, resulting in a net loss of $21.8 million. Adjusted EBITDA loss was $13.2 million. Butterfly Network raised its full year guidance for 2024 to $75-80 million in revenue, with an adjusted EBITDA loss of $55-50 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.